Evaluation of testosterone levels in men with metabolic syndrome

Basit Öğe Kaydı
dc.contributor.authorIltumur, Kenan
dc.contributor.authorKarabulut, Aziz
dc.contributor.authorToprak, Gulten
dc.contributor.authorYokus, Beran
dc.contributor.authorToprak, Nizamettin
dc.date.accessioned2024-04-24T17:33:53Z
dc.date.available2024-04-24T17:33:53Z
dc.date.issued2005
dc.departmentDicle Üniversitesien_US
dc.description.abstractObjectives: Low plasma levels of testosterone in men are associated with increased risk for atherosclerosis. In this study, we assessed plasma testosterone levels in patients with metabolic syndrome (MS) and its relationship with MS parameters. Study design: The study consisted of 36 men (mean age 50.2 +/- 7.2 years) with a diagnosis of MS according to the NCEP (National Cholesterol Education Program) criteria. An age-matched control group comprising 39 healthy volunteers (mean age 48.3 +/- 8.1 years) was also included. Plasma testosterone levels were determined by electro-chemiluminescence immunoassay on the Roche Elecsys 2010 analyzer. Fasting blood samples were analyzed for glucose and insulin levels, and lipid profiles (total cholesterol, triglyceride, LDL, and HDL). In addition, HOMA (Homeostasis Model Assessment) index was calculated. Results: The mean plasma testosterone level was significantly lower in the patient group (3.6 +/- 0.8 vs 4.8 +/- 1.9 ng/ml, p=0.001). There was a significant correlation between the levels of testosterone and HDL cholesterol (r=0.25, p<0.05). Testosterone levels were inversely correlated with the following: body mass index (r=-0.41, p<0.001), waist circumference (r=-0.40, p<0.001), HOMA index (r=-0.31, p=0.008), insulin (r=-0.28, p<0.05), glucose (r=-0.29, p<0.05), triglyceride (r=-0.28, p<0.05), and very low density lipoprotein (r=-0.28, p<0.05). Multivariate analysis identified only body mass index as an independent correlate of testosterone (beta=-0.36, p=0.038). Conclusion: Our results show that plasma testosterone levels are significantly decreased in MS. This may be of clinical importance for the assessment of cardiovascular risks in male patients with MS.en_US
dc.identifier.endpage451en_US
dc.identifier.issn1016-5169
dc.identifier.issue8en_US
dc.identifier.scopus2-s2.0-39749167753
dc.identifier.scopusqualityQ3
dc.identifier.startpage447en_US
dc.identifier.urihttps://hdl.handle.net/11468/20879
dc.identifier.volume33en_US
dc.identifier.wosWOS:000421383600001
dc.identifier.wosqualityN/A
dc.indekslendigikaynakWeb of Science
dc.indekslendigikaynakScopus
dc.language.isotren_US
dc.publisherTurkish Soc Cardiologyen_US
dc.relation.ispartofTurk Kardiyoloji Dernegi Arsivi-Archives of The Turkish Society of Cardiology
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanıen_US
dc.rightsinfo:eu-repo/semantics/closedAccessen_US
dc.subjectBody Mass Indexen_US
dc.subjectInsulin Resistance/Physiologyen_US
dc.subjectMaleen_US
dc.subjectMetabolic Syndrome X/Blooden_US
dc.subjectObesityen_US
dc.subjectTestosterone/Blooden_US
dc.titleEvaluation of testosterone levels in men with metabolic syndromeen_US
dc.titleEvaluation of testosterone levels in men with metabolic syndrome
dc.typeArticleen_US

Dosyalar

Koleksiyon

WoS İndeksli Yayınlar Koleksiyonu
Scopus İndeksli Yayınlar Koleksiyonu